{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:03:05Z","timestamp":1793329385355,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1681\/asn.2014010046","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:05:48Z","timestamp":1415405148000},"page":"976-985","source":"Crossref","is-referenced-by-count":153,"title":["Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement"],"prefix":"10.1681","volume":"26","author":[{"given":"Duvuru","family":"Geetha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees G.M.","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. William","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barri J.","family":"Fessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linna","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia K.","family":"Tchao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230208","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis).","volume":"2","author":"Walton","year":"1958","journal-title":"BMJ"},{"key":"R2-25-20230208","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: An analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"R3-25-20230208","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years.","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"R4-25-20230208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R5-25-20230208","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis.","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-25-20230208","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis.","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-25-20230208","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: Modification of the Birmingham Vasculitis Activity Score.","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R8-25-20230208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876539401104010001","article-title":"Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial.","volume":"4","author":"Specks","year":"2011","journal-title":"Open Arthritis J"},{"key":"R9-25-20230208","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"R10-25-20230208","first-page":"55","article-title":"Guidelines for the management of rapidly progressive glomerulonephritis.","volume":"44","author":"Sakai","year":"2002","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"R11-25-20230208","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis.","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"R12-25-20230208","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R13-25-20230208","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): Ten-year experience at a single center.","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R14-25-20230208","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R15-25-20230208","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial.","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"R16-25-20230208","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10875-005-3863-2","article-title":"Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis.","volume":"25","author":"Damoiseaux","year":"2005","journal-title":"J Clin Immunol"},{"key":"R17-25-20230208","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R18-25-20230208","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"R19-25-20230208","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R20-25-20230208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201504000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:25:25Z","timestamp":1786130725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201504000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014010046","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}